Managers / Q2 2023 · view latest →
M28 Capital Management LP
CIK 0001807489 · 700 CANAL STREET, 1ST FLOOR, STAMFORD, CT, 06902 · 203-516-3730
Summary
M28 Capital Management LP reported $76M in U.S.-listed holdings across 12 positions for Q2 2023.
The portfolio is heavily concentrated: WVE alone accounts for 33.9% of reported value.
Compared with Q1 2023, the fund opened 0 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 86.7% · $66M
- Other · 10.7% · $8M
- ADR · 2.6% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SLNSILENCE THERAPEUTICS PLC | ADDED | +217.9K | 363.8K | +$1M | $2M |
| IONSIONIS PHARMACEUTICALS INC | SOLD OUT | −126.3K | 0 | −$5M | $0 |
| ATARA BIOTHERAPEUTICS INC | SOLD OUT | −439.3K | 0 | −$1M | $0 |
| TGTXTG THERAPEUTICS INC | TRIMMED | −197.0K | 142.5K | −$2M | $4M |
| BBIOBRIDGEBIO PHARMA INC | TRIMMED | −138.5K | 166.2K | −$2M | $3M |
| STOKSTOKE THERAPEUTICS INC | TRIMMED | −186.7K | 346.2K | −$758,974 | $4M |
| CURIS INC | ADDED | +1.52M | 6.00M | +$2M | $5M |
| RCKTROCKET PHARMACEUTICALS INC | TRIMMED | −91.7K | 630.4K | +$156,421 | $13M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | WVEWAVE LIFE SCIENCES LTDhistory → | SHS | 33.91% | $26M | 7.05M |
| 2 | RCKTROCKET PHARMACEUTICALS INChistory → | COM | 16.55% | $13M | 630.4K |
| 3 | IVVDINVIVYD INChistory → | COM | 12.83% | $10M | 9.25M |
| 4 | SPRINGWORKS THERAPEUTICS INC | COM | 6.85% | $5M | 197.7K |
| 5 | CURIS INC | COM NEW | 6.58% | $5M | 6.00M |
| 6 | STOKSTOKE THERAPEUTICS INChistory → | COM | 4.86% | $4M | 346.2K |
| 7 | TGTXTG THERAPEUTICS INChistory → | COM | 4.68% | $4M | 142.5K |
| 8 | PROQR THRAPEUTICS N V | SHS EURO | 4.09% | $3M | 1.91M |
| 9 | BBIOBRIDGEBIO PHARMA INChistory → | COM | 3.78% | $3M | 166.2K |
| 10 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 3.18% | $2M | 67.4K |
| 11 | SLNSILENCE THERAPEUTICS PLChistory → | ADS | 2.64% | $2M | 363.8K |
| 12 | NEXIMMUNE INC | COM | 0.05% | $37,604 | 133.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $54M | 9 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $138M | 9 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $68M | 9 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $59M | 9 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $73M | 11 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $102M | 11 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $91M | 11 | Nov 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $77M | 11 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $135M | 11 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 10 | Feb 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $87M | 11 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $76M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $88M | 14 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $105M | 14 | Feb 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $96M | 12 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $89M | 13 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $109M | 13 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $128M | 12 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.